Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens-Reference-Cited by-同舟云学术

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens

Published:2021-07-22 Issue:11 Volume:61 Page:1493-1504
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Cohen‐Rabbie Sarit¹,Zhou Li²,Vishwanathan Karthick²^ORCID,Wild Martin³,Xu Sherrie⁴,Freshwater Tomoko⁵,Jain Lokesh⁵,Schalkwijk Stein¹,Tomkinson Helen¹,Zhou Diansong²

Affiliation:

1. Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D AstraZeneca Cambridge UK

2. Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D AstraZeneca Boston Massachusetts USA

3. DMPK, Oncology AstraZeneca Cambridge UK

4. Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) Merck & Co., Inc. Kenilworth New Jersey USA

5. Quantitative Pharmacology & Pharmacometrics (QP2) Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) Merck & Co., Inc. Kenilworth New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1935

Reference22 articles.

1. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

2. US Food and Drug Administration. Koselugo (selumetinib) prescribing information. AstraZeneca Pharmaceuticals LP.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf. Accessed October 5 2020.

3. Population Pharmacokinetic and Exposure‐Response Analysis of Selumetinib and Its N‐desmethyl Metabolite in Patients With Non‐Small Cell Lung Cancer

4. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects

5. Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Modeling Approaches for Oral Drug Delivery: Artificial Intelligence, Physiologically-Based Pharmacokinetics, and First-Principles Models;Pharmaceutics;2024-07-24

2. Triazole antifungal drug interactions—practical considerations for excellent prescribing;Journal of Antimicrobial Chemotherapy;2024-04-17

3. A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-04-09

4. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19

5. Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors;Clinical and Translational Science;2023-04-18